Full Text View
Tabular View
No Study Results Posted
Related Studies
Multiple Dose Trial of Anti-Glycation Agent GLY-230 in Healthy and Diabetic Subjects
This study has been completed.
First Received: October 15, 2007   No Changes Posted
Sponsored by: Glycadia
Information provided by: Glycadia
ClinicalTrials.gov Identifier: NCT00544934
  Purpose

A dose-ranging study evaluating safety, metabolism and therapeutic dosing of three multiple dose levels of GLY-230 in healthy and diabetic subjects


Condition Intervention Phase
Diabetic Nephropathy
 Drug: GLY-230
 Phase I
Phase II

MedlinePlus related topics: Diabetic Kidney Problems
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind (Subject), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Dose-Ranging Study to Evaluate the Safety, Metabolism and Therapeutic Dosing of Three Multiple Dose Levels of GLY-230 in Healthy and Diabetic Subjects

Further study details as provided by Glycadia:

Primary Outcome Measures:
  • glycated albumimin concentration [ Time Frame: three weeks ]

Secondary Outcome Measures:
  • urine albumin [ Time Frame: three weeks ]

Enrollment: 42
Study Start Date: February 2007
Study Completion Date: October 2007
Intervention Details:
    Drug: GLY-230
    125, 250 0r 375 mg bid for 14 days
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Nondiabetic and diabetic men age 18-55, engative drug screen, normal EKG, clinical chemistries. hematology parameters, HbA1c 7.5% if diabetic, give written informed consent

Exclusion Criteria:

  • Sctive concomitant serious medical or surgical disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00544934

Sponsors and Collaborators
Glycadia
Investigators
Principal Investigator: Laurence Kennedy, M.D. University of Florida
Principal Investigator: Maria del Pilar Solano, M.D. University of Miami, Miami, Florida
Principal Investigator: Lis Cohen, D.O. Suncoast Clinical Research, New Port Richey, Florida
  More Information

No publications provided

Study ID Numbers: GLY-002
Study First Received: October 15, 2007
Last Updated: October 15, 2007
ClinicalTrials.gov Identifier: NCT00544934     History of Changes
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Diabetic Nephropathies
Urologic Diseases
Diabetes Mellitus
Endocrine System Diseases
 Endocrinopathy
Healthy
Kidney Diseases
Diabetes Complications

Additional relevant MeSH terms:
Diabetic Nephropathies
Urologic Diseases
Diabetes Mellitus
 Endocrine System Diseases
Kidney Diseases
Diabetes Complications

ClinicalTrials.gov processed this record on May 06, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services